Microneedling pens for hair loss, with users discussing brands like Korabeauticals v2, Dr Pen, and Derminator 2. Some users report using oral minoxidil but have not seen regrowth yet.
The user is using topical minoxidil 5% with 0.1% finasteride, ketoconazole shampoo, and a derma roller for hair regrowth. There is some progress, but it's hard to assess due to varying hair lengths.
The user has been using topical finasteride for seven months and minoxidil for three years, with added tretinoin gel for ten months, and is experiencing continuous shedding without signs of regrowth. They are questioning if the amount of shedding is normal at this stage of treatment and if there's a correlation between finasteride response and the rate of hair loss.
A 22-year-old male experienced significant hair regrowth after 4 months using minoxidil, finasteride, and dermarolling. He reported initial mild testicular pain but no other side effects, and he uses a 1mm and 0.5mm dermaroller.
MaximusDurkimus shares experience with 0.25mg Finasteride, Minoxidil-induced lupus, and less than 10mg RU58841 for hair loss. Plans to try 0.025% topical Finasteride with 5% Stemoxydine and possibly Tretinoin, Fluridil, or CB-03-01 in the future.
The user has been using finasteride 1mg and minoxidil 5% daily, along with Nizoral 2% twice a week for 16 months, and has seen improvement in hair regrowth, moving from Norwood 4 to between Norwood 2 and 3. The minoxidil used is a local pharmacy brand.
The conversation discusses hair loss treatment progress using Minoxidil, a 0.5mm derma stamp, and caffeine serum, with additional use of rosemary, peppermint, and olive oil. The user is avoiding DHT blockers like Finasteride due to potential interference with other medications.
Using lice as an alternative to microneedling for hair loss treatment, with concerns about effectiveness and practicality. Some users humorously suggest genetically altering lice to produce beneficial compounds.
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.